Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma
Vicki Goodman, Richard Pazdur(United States Food and Drug Administration), Edwin P. Rock, Cheng Yi Liang, S. Leigh Verbois, Kooros Mahjoob(Cancer Research And Biostatistics), Robert Justice(United States Food and Drug Administration), Janet Jiang(Cancer Research And Biostatistics), Shenghui Tang(United States Food and Drug Administration), Jogarao Gobburu(University of Maryland, Baltimore), Ramzi Dagher, Sophia Abraham(United States Food and Drug Administration), Roshni Ramchandani, Nallaperumal Chidambaram, Brian Booth, David E. Morse(United States Food and Drug Administration)
Cited by 495
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k